Postmenopausal hormone therapy and migraine headache
Postmenopausal hormone therapy and migraine headache
复制标题
DOI：
10.1089/154099903322643956
复制
发表时间：
2003-12-01
影响因子：
3.5
通讯作者：
Rexrode, KM
中科院分区：
文献类型：
--
作者：
Misakian, AL;Langer, RD;Rexrode, KM
背景资料：雌激素戒断被描述为偏头痛的触发因素，一些研究表明雌激素和孕酮可能会加剧偏头痛。没有基于人群的研究探讨激素治疗（HT）和绝经后妇女偏头痛之间的关联。方法：为了研究绝经后妇女HT和偏头痛之间的关联，我们在过去一年中对参加妇女健康研究的17，107名绝经后女性健康专业人员进行了HT使用、HT特征和偏头痛的自我报告。结果：分析仅限于21，788名绝经后妇女中的17，107名，这些妇女在基线时已绝经，从未（38.5%）或目前（61.5%）使用HT。其中，1，909人（11.2%）在过去一年内经历过偏头痛。患有偏头痛的女性明显更年轻，绝经年龄更小，更可能有手术绝经，更可能是HT的当前用户。调整年龄、种族、吸烟、饮酒、口服避孕药使用史、绝经年龄和绝经类型后，目前使用HT的女性与从未使用HT的女性相比，偏头痛的优势比（OR）为1.42（95%CI 1.24-1.62）。单独使用雌激素（OR 1.39，95%CI 1.14-1.69）和同时使用雌激素和炔雌醇（OR 1.41，95%CI 1.22-1.63）的OR相似。需要临床试验来确定HT是否会增加绝经后妇女偏头痛的发病率。
Background: Estrogen withdrawal has been described as a trigger for migraine headache, and some studies suggest that estrogen and progestin may exacerbate migraine. No population-based studies have examined the association between hormone therapy (HT) and migraine among postmenopausal women.Methods: To examine the association between HT and migraine headache in postmenopausal women, we used self-report of HT use, HT characteristics, and migraine headache within the past year among 17,107 postmenopausal female health professionals enrolled in the Women's Health Study.Results: Analyses were restricted to the 17,107 of 21,788 postmenopausal women who were postmenopausal at baseline and who were never (38.5%) or current (61.5%) users of HT. Of these, 1,909 (11.2%) experienced migraine headache within the last year. Women with migraine headache were significantly younger, had a younger age at menopause, were more likely to have had a surgical menopause, and were more likely to be current users of HT. After adjusting for age, race, smoking, alcohol use, ever use of oral contraception, age at menopause, and menopause type, the odds ratio (OR) for migraine headache was 1.42 (95% CI 1.24-1.62) for women who were current users of HT compared with never users. ORs were similar for users of estrogen alone (OR 1.39, 95% CI 1.14-1.69) and users of both estrogen and progestin (OR 1.41, 95% CI 1.22-1.63).Conclusions: In this cross-sectional study, current HT use was associated with higher rates of migraine headache than nonuse. Clinical trials are needed to determine if HT increases the incidence of migraine in postmenopausal women.